GPC3 and neoplasm: Accordingly, we aimed to: (I) assess the diagnostic accuracy of serum GPC-3 for distinguishing HCC from cirrhosis without tumor; (II) evaluate whether baseline post-SVR GPC-3 predicts de novo HCC during the follow-up (FU); and (III) determine the prognostic value of GPC-3 in patients with established HCC.